Athena Athena

X
[{"orgOrder":0,"company":"Anova Pharma","sponsor":"NeOnc Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anova Partners with NeOnc Technologies to Bring NEO100 to Patients With IDH1 Mutated Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"VIETNAM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Anova Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.

            Lead Product(s): Perillyl Alcohol

            Therapeutic Area: Oncology Product Name: NEO100

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NeOnc Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY